NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

Published

Journal Article

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

Full Text

Duke Authors

Cited Authors

  • Ettinger, DS; Wood, DE; Akerley, W; Bazhenova, LA; Borghaei, H; Camidge, DR; Cheney, RT; Chirieac, LR; D'Amico, TA; Dilling, TJ; Dobelbower, MC; Govindan, R; Hennon, M; Horn, L; Jahan, TM; Komaki, R; Lackner, RP; Lanuti, M; Lilenbaum, R; Lin, J; Loo, BW; Martins, R; Otterson, GA; Patel, JD; Pisters, KM; Reckamp, K; Riely, GJ; Schild, SE; Shapiro, TA; Sharma, N; Stevenson, J; Swanson, SJ; Tauer, K; Yang, SC; Gregory, K; Hughes, M

Published Date

  • March 2016

Published In

Volume / Issue

  • 14 / 3

Start / End Page

  • 255 - 264

PubMed ID

  • 26957612

Pubmed Central ID

  • 26957612

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2016.0031

Language

  • eng

Conference Location

  • United States